18
Oct
2012
Posted in I - Series C, Q - 1Q12, R - WEST, X - CNS, X - Device (Aneurysm), XX - CA
Sequent Medical (Aliso Viejo, CA) a commercial-stage medical device company focused on endovascular embolic coils devices for ruptured and non-ruptured intracranial aneurysms, closed a $26M Series C financing. Participants include Delphi Ventures, Versant Ventures, US Venture Partners and Domain Associates. Note: Closing out 1Q deals. Thanx for your patience as we play catch-up.
06
Mar
2012
15
Feb
2012
07
Feb
2012
Posted in I - Series A, Q - 4Q11, R - ROCKY MOUNTAIN, X - Device (Diagnostic), XX - UT
Sera Prognostics (Salt Lake City, UT) a development-stage diagnostic company focused on preterm birth and other pregnancy complications, closed a $19.3M Series A financing. Participants include InterWest Partners, Domain Associates, Catalyst Health Ventures, UpStart Life Sciences Capital and Osage University Partners.
06
Feb
2012
Posted in I - Series C, Q - 4Q11, R - WEST, X - Device (Sequencing), X - Sample Prep, XX - CA
IntegenX (Pleasanton, CA) a commercial-stage device company focused on sample preparation for next generation sequencing, closed a $40M Series C financing. Participants include Essex Woodlands, Domain Associates, QuestMark Partners, Greenspring Associates, Cross Creek Capital, Rona Holdings, Samsung Ventures and In-Q-Tel.
22
Jul
2011
17
Jul
2011
29
Apr
2011
27
Apr
2011
29
Mar
2011
Posted in I - Series B, Q - 1Q11, R - NORTH EAST, X - Device (Diagnostic), XX - PA
BioNanomatrix (Philadelphia, PA) commercial-stage developer of a nanochannel array chip, single-molecule imaging and analysis platform, closed a $23.3M Series B financing. Participants include Domain Associates, Gund Investment Corp., Battelle Ventures, Innovation Valley Partners and KT Venture Group.
22
Nov
2010
Posted in I - Series B, Q - 4Q10, R - NORTH EAST, X - RNAi, XX - MA
Dicerna Pharmaceuticals (Cambridge, MA) a development-stage biopharmaceutical company focused on the development RNAi-based therapeutics, closed a $4M Series B financing, bringing the total round to $29M. Participants include SR One, Domain Associates, Oxford Bioscience Partners, Abingworth Management and Skyline Ventures.
19
Nov
2010
01
Oct
2010